I'm a Dermatopathologist. Retatrutide's Skin Burning Is Concerning.
A dermatopathologist argues that retatrutide's skin and nerve burning is unstudied under a microscope, and that unverified online vials add further unknowns. He offers a five-question checklist.
With Dr. Amin Hedayat (MD)
Key moments
Tap a moment to play the video from there.
- 0:00The missing skin biopsyHedayat says no microscopic studies or biopsies of retatrutide's skin and nerve reaction have been published, and that this absence worries him.
- 3:34Two doors: official or gray marketHe describes the cost and access barriers of the official path and the appeal and uncertainty of buying vials online.
- 5:03Approved, investigational, untestedHe sorts semaglutide, tirzepatide, retatrutide and tesamorelin by regulatory status and trial history.
- 7:45The chain of custody ideaHe uses the evidence-handling analogy to argue that every step from manufacture to injection should be traceable.
- 9:19What could be in the vialHe says the FDA does not test research peptides, that seller verification claims are often vague, and that label contents cannot be trusted.
- 11:30Bacteriostatic water and infection riskHe explains what bacteriostatic water does and does not do, the 28-day rule, and infections he has seen on biopsy tissue.
- 14:07What the trials showHe reviews weight loss results and the pancreatitis, heart rate, liver and GI signals, stressing the short follow-up.
- 15:57Dysesthesia and the missing biopsyHe gives the reported rates of the burning and tingling reaction and says no biopsy of it has been published.
- 17:57The low dose objectionHe argues that a low dose does not address purity, contamination or the lack of supervision.
- 19:52Tesamorelin and retatrutide stackHe explains tesamorelin's limited approval and a theoretical IGF-1 concern, and says the combination has no human data.
What the video says
Dr. Amin Hedayat, a dermatopathologist who describes himself as triple board certified, argues that retatrutide, an investigational weight loss drug, has produced a skin and nerve reaction called dysesthesia that no published study has examined under a microscope. He says there are no biopsies of it in the literature. He states that he has no financial ties to peptide sellers or drug makers and that the video is not sponsored.
He first lays out the landscape. Semaglutide and tirzepatide are FDA approved with large trials behind them. Retatrutide is not approved. He cites a phase 2 result of 24.2% body weight loss at 48 weeks and a Triumph 4 result of 28.7% at 68 weeks, and says FDA review is projected around 2027 to 2028. Tesamorelin, he says, is approved only for HIV-associated lipodystrophy, and he states that the combination of tesamorelin and retatrutide has no published human studies and exists only in forum protocols.
The central idea is a "chain of custody" for anything injected. He contrasts the official path, where each link is documented, with the gray market, where he says most links cannot be traced. He says the FDA does not test compounded or research peptides for purity or quality, that "research use only" labels protect the seller, and that he cannot tell whether a labeled vial contains the right molecule. He also walks through bacteriostatic water, a 28-day rule for opened vials, and injection infections he says he has seen in biopsies, and presents this as a map of risks, not instructions.
On dysesthesia, he gives a range of roughly 1 in 8 to 1 in 5 people at higher doses, says most cases were mild and eased, and answers the "I take a low dose" objection by saying dose is only one variable. He closes with a five-question "vial audit" covering origin, identity, evidence, supervision and exit, and promotes a free download and an upcoming program. The talk is a cautionary one from a single clinician and is aimed at people considering unverified products.
On each compound
Retatrutide1:02
Hedayat calls retatrutide investigational and cites 24.2% weight loss at 48 weeks in phase 2 and 28.7% at 68 weeks in Triumph 4. He says higher doses were linked to dysesthesia in roughly 1 in 8 to 1 in 5 people, with no published biopsy, and that gray market vials cannot be verified.
See how your DNA reads RetatrutideTesamorelin19:52
Hedayat says tesamorelin was approved in 2010 only for HIV-associated lipodystrophy and was not studied in healthy adults for body composition. He raises a theoretical concern about sustained IGF-1 elevation and says the combination with retatrutide has no published human study.
See how your DNA reads Tesamorelin“A forum testimonial is a Google review for your pancreas.”
What this video doesn’t settle
- Hedayat is a dermatopathologist and not a trial investigator, and he reasons from published trial figures without showing the underlying data.
- The dysesthesia rates he cites vary widely between trials, and he does not establish what causes the reaction.
- He gives no data on how often gray market vials are actually contaminated or mislabeled; the contents risk is argued in principle.
Questions this video answers
What skin reaction does Dr. Hedayat link to retatrutide?
He describes dysesthesia, a neurocutaneous reaction with burning, tingling and pain from normal touch. He says it was reported in roughly 1 in 8 to 1 in 5 people at higher doses in trials, and that most cases were mild and eased.
Has retatrutide dysesthesia been studied with skin biopsies?
Hedayat says no biopsy or microscopic study of the reaction has been published. He presents this as the main gap in what is known about it.
What does Hedayat say about buying retatrutide online?
He says the FDA does not test research peptides for purity or quality, and that a vial's label cannot show what is inside. He also says that if skin burning occurs, a buyer cannot tell whether the molecule, an impurity or contamination is responsible.
Does Hedayat say a low dose of retatrutide is safe?
He says no. In his view not every signal is dose dependent, a low dose of an impure product is a different drug, and trial dose data come from supervised conditions that a home setting does not replicate.
What is the vial audit Hedayat describes?
It is a five-question checklist covering origin, identity, evidence, supervision and an exit plan. He says that if you cannot answer all five cleanly, that points to a gap in your chain of custody.
Video by Dr. Amin Hedayat, MD on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
